DK1526867T3 - Erythropoietin i subpolycytæmiske doser - Google Patents
Erythropoietin i subpolycytæmiske doserInfo
- Publication number
- DK1526867T3 DK1526867T3 DK03766302T DK03766302T DK1526867T3 DK 1526867 T3 DK1526867 T3 DK 1526867T3 DK 03766302 T DK03766302 T DK 03766302T DK 03766302 T DK03766302 T DK 03766302T DK 1526867 T3 DK1526867 T3 DK 1526867T3
- Authority
- DK
- Denmark
- Prior art keywords
- epo
- tissue
- endothelial
- derivatives
- stimulating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10234192A DE10234192B4 (de) | 2002-07-26 | 2002-07-26 | Verwendung von Erythropoetin |
PCT/EP2003/008229 WO2004012759A2 (de) | 2002-07-26 | 2003-07-25 | Erythropoetin zur stimulation endothelialer voläuferzellen |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1526867T3 true DK1526867T3 (da) | 2007-09-17 |
Family
ID=30128436
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07001689.4T DK1779862T3 (da) | 2002-07-26 | 2003-07-25 | Erythropoietin i subpolycytæmiske doser til behandling af diabetes |
DK03766302T DK1526867T3 (da) | 2002-07-26 | 2003-07-25 | Erythropoietin i subpolycytæmiske doser |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07001689.4T DK1779862T3 (da) | 2002-07-26 | 2003-07-25 | Erythropoietin i subpolycytæmiske doser til behandling af diabetes |
Country Status (27)
Country | Link |
---|---|
US (4) | US7745387B2 (pt) |
EP (3) | EP1526867B1 (pt) |
JP (4) | JP4727988B2 (pt) |
KR (2) | KR20100077033A (pt) |
CN (3) | CN101099731B (pt) |
AT (2) | ATE360436T1 (pt) |
AU (2) | AU2003255290B2 (pt) |
BR (1) | BR0312981A (pt) |
CA (2) | CA2710100A1 (pt) |
CY (2) | CY1108052T1 (pt) |
DE (3) | DE10234192B4 (pt) |
DK (2) | DK1779862T3 (pt) |
EA (3) | EA013966B1 (pt) |
ES (2) | ES2345673T3 (pt) |
HK (2) | HK1081841A1 (pt) |
HR (3) | HRP20050065A2 (pt) |
IL (2) | IL166401A0 (pt) |
IS (3) | IS2671B (pt) |
MX (1) | MXPA05001120A (pt) |
NO (1) | NO20051002L (pt) |
PL (2) | PL374874A1 (pt) |
PT (2) | PT1526867E (pt) |
SG (1) | SG177004A1 (pt) |
SI (2) | SI1779862T1 (pt) |
UA (2) | UA85997C2 (pt) |
WO (1) | WO2004012759A2 (pt) |
ZA (1) | ZA200500726B (pt) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723303B2 (en) | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
KR101192136B1 (ko) * | 2003-07-29 | 2012-10-16 | 돔페 파르마 에스.피.에이. | 혈액 줄기 세포의 동원에 유효한 g-csf와 plgf의조합 약제 |
DK2233150T3 (en) * | 2003-12-30 | 2016-12-12 | Augustinus Bader | Erythropoietin for use in the treatment of wounds or transplantation of cells |
DE102004063927A1 (de) * | 2004-01-23 | 2005-12-15 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
CA2595067A1 (en) | 2004-12-06 | 2006-06-15 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
AR053416A1 (es) | 2005-11-10 | 2007-05-09 | Protech Pharma S A | Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac |
EP1973559B1 (en) | 2005-11-23 | 2013-01-09 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for promoting bone growth |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
AR061269A1 (es) * | 2006-06-07 | 2008-08-13 | Chugai Pharmaceutical Co Ltd | Composicion y metodo de revascularizacion para el tratamiento de enfermedades isquemicas usando eritropoyetina |
BRPI0717155A2 (pt) * | 2006-09-29 | 2013-10-15 | Centocor Ortho Biotech Inc | Agonistas do receptor de epo humana, composições, métodos e usos para prevenção ou tratamento das condições relacionadas á intolerância á glicose |
AU2007311946A1 (en) | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient |
US8975374B2 (en) * | 2006-10-20 | 2015-03-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient |
EP3040347A3 (en) * | 2006-10-20 | 2016-09-21 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
JP2010515736A (ja) * | 2007-01-10 | 2010-05-13 | エジソン ファーマシューティカルズ, インコーポレイテッド | エリスロポイエチン活性またはトロンボポイエチン活性を有する化合物を用いる呼吸鎖障害の治療 |
TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
AR065613A1 (es) * | 2007-03-09 | 2009-06-17 | Chugai Pharmaceutical Co Ltd | Agentes de proteccion para organos transplantados |
EP2192907B1 (en) * | 2007-08-16 | 2018-04-18 | Remedor Biomed Ltd. | Erythropoietin and fibronectin compositions for therapeutic applications |
CA2724841A1 (en) * | 2008-05-22 | 2009-11-26 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with an erythropoietin mimetic |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
DK2340031T3 (da) | 2008-08-14 | 2019-07-15 | Acceleron Pharma Inc | Gdf-fanger til anvendelse ved behandling af anæmi |
MX2011013172A (es) | 2009-06-08 | 2012-04-02 | Acceleron Pharma Inc | Metodos para aumentar adipocitos termogenicos. |
KR20120028358A (ko) | 2009-06-12 | 2012-03-22 | 악셀레론 파마 인코포레이티드 | 절두된 ActRIIB-FC 융합 단백질 |
IL287990B (en) * | 2009-08-13 | 2022-07-01 | Acceleron Pharma Inc | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
EP3332796A1 (en) | 2009-11-17 | 2018-06-13 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
EP2590666B1 (en) | 2010-07-06 | 2017-04-26 | Augustinus Bader | Topical application of erythropoietin for use in the treatment of injuries of the cornea |
WO2012148200A2 (ko) * | 2011-04-26 | 2012-11-01 | 아주대학교 산학협력단 | 허혈성 혈관 질환 치료시술 보조용 조성물 |
KR20210091358A (ko) | 2012-11-02 | 2021-07-21 | 셀진 코포레이션 | 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도 |
US8992951B2 (en) | 2013-01-09 | 2015-03-31 | Sapna Life Sciences Corporation | Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma |
EP3060174B1 (en) * | 2013-10-22 | 2020-05-27 | Concievalve LLC | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
WO2015192111A1 (en) | 2014-06-13 | 2015-12-17 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
EP3543339A1 (en) | 2015-02-13 | 2019-09-25 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
CN105233256A (zh) * | 2015-10-28 | 2016-01-13 | 中国人民解放军第三军医大学 | ***及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用 |
US11534466B2 (en) * | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
GB2550114A (en) * | 2016-05-03 | 2017-11-15 | Kymab Ltd | Methods, regimens, combinations & antagonists |
AU2017312113B2 (en) | 2016-08-17 | 2023-05-25 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
CN108114282B (zh) * | 2016-11-28 | 2021-03-02 | 北京大学第三医院 | 他汀类化合物治疗缺血性疾病的用途 |
WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
US11692037B2 (en) | 2017-10-20 | 2023-07-04 | Hyogo College Of Medicine | Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion |
RU2678768C1 (ru) * | 2018-09-25 | 2019-02-01 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики ишемически-реперфузионных повреждений почек карбамилированным дарбэпоэтином в эксперименте |
RU2695334C1 (ru) * | 2018-09-25 | 2019-07-23 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики нарушений функций почек карбамилированным дарбэпоэтином в эксперименте |
US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin |
US4732889A (en) | 1985-02-06 | 1988-03-22 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis |
US5198417A (en) * | 1985-11-27 | 1993-03-30 | Genetics Institute, Inc. | Methods of treating pancytopenia and AIDS by co-administering EPO and colony stimulating factors |
DE3686582T2 (de) | 1985-11-27 | 1993-01-28 | Genetics Inst | Behandlung einer krankheit vom aids-typ. |
DK173067B1 (da) | 1986-06-27 | 1999-12-13 | Univ Washington | Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa |
US5013718A (en) | 1986-11-21 | 1991-05-07 | Amgen, Inc. | Method for treating iron overload using EPO |
DE3729863A1 (de) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
AU4072189A (en) * | 1988-02-24 | 1989-09-22 | American National Red Cross, The | Device for site directed neovascularization and method for same |
US5024841A (en) * | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
DE4014654A1 (de) | 1990-05-08 | 1991-11-14 | Behringwerke Ag | Galenische waessrige formulierungen von erythropoietin und ihre verwendung |
ATE203166T1 (de) * | 1991-03-11 | 2001-08-15 | Curis Inc | Protein-induzierende morphogenese |
US5354934A (en) * | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
KR960701650A (ko) | 1993-04-29 | 1996-03-28 | 찰스 엠. 브룩 | 에리트로포이에틴 유사체 조성물 및 방법(Eythropoietin analog compositions and methods) |
ZA946122B (en) | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
JPH08205860A (ja) * | 1994-01-21 | 1996-08-13 | Usa Government | 造血細胞の膨大化および移植方法 |
ITFI940106A1 (it) * | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica |
WO1996014081A1 (en) | 1994-11-03 | 1996-05-17 | Boehringer Mannheim Gmbh | Use of erythropoietin in the treatment of rheumatoid arthritis |
US5837675A (en) * | 1995-02-03 | 1998-11-17 | Brox; Alan G. | Synergistic effect of insulin-like growth factor-I and erythropoietin |
US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
US5980887A (en) * | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
US6284260B1 (en) | 1998-02-04 | 2001-09-04 | Veronica L. Zaharia Czeizler | Treatment with erythropoietin of bleeding from benign and malignant lesions with normal and abnormal coagulation parameters |
US6274158B1 (en) * | 1998-02-04 | 2001-08-14 | Veronica L. Zaharia Czeizler | Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis |
DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
EA004766B1 (ru) * | 1999-04-13 | 2004-08-26 | Дзе Кеннет С. Уоррен Инститьют, Инк. | Модуляция функции возбуждаемых тканей за счет периферического введения эритропоэтина |
DE60131393D1 (de) | 2000-05-02 | 2007-12-27 | Action Pharma As | Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände |
US7259146B2 (en) * | 2000-05-26 | 2007-08-21 | Ortho-Mcneil Pharmaceutical, Inc. | Neuroprotective peptides |
US7078376B1 (en) * | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
US20020065214A1 (en) | 2000-11-29 | 2002-05-30 | Adrian Iaina | Method of treating congestive heart failure |
PA8536201A1 (es) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
WO2002085940A2 (en) * | 2001-04-04 | 2002-10-31 | Genodyssee | New polynucleotides and polypeptides of the erythropoietin gene |
US6784154B2 (en) * | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
EP1461065A1 (en) * | 2001-11-28 | 2004-09-29 | Ortho-McNeil Pharmaceutical, Inc. | Erythropoietin dosing regimen for treating anemia |
US7335490B2 (en) | 2002-01-09 | 2008-02-26 | Crucell Holland B.V. | Use of erythropoietin for the preventive or curative treatment of cardiac failure |
US6748154B2 (en) * | 2002-03-28 | 2004-06-08 | Nortel Networks Limited | Optical module access tray |
DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
DE102004063927A1 (de) * | 2004-01-23 | 2005-12-15 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
-
2002
- 2002-07-26 DE DE10234192A patent/DE10234192B4/de not_active Expired - Fee Related
-
2003
- 2003-07-25 UA UAA200501760A patent/UA85997C2/ru unknown
- 2003-07-25 DK DK07001689.4T patent/DK1779862T3/da active
- 2003-07-25 DE DE50312729T patent/DE50312729D1/de not_active Expired - Lifetime
- 2003-07-25 PL PL03374874A patent/PL374874A1/xx unknown
- 2003-07-25 EP EP03766302A patent/EP1526867B1/de not_active Expired - Lifetime
- 2003-07-25 SI SI200331837T patent/SI1779862T1/sl unknown
- 2003-07-25 AT AT03766302T patent/ATE360436T1/de not_active IP Right Cessation
- 2003-07-25 UA UAA200801307A patent/UA94913C2/ru unknown
- 2003-07-25 ES ES07001689T patent/ES2345673T3/es not_active Expired - Lifetime
- 2003-07-25 EP EP07001689A patent/EP1779862B1/de not_active Expired - Lifetime
- 2003-07-25 CA CA2710100A patent/CA2710100A1/en not_active Abandoned
- 2003-07-25 AU AU2003255290A patent/AU2003255290B2/en not_active Ceased
- 2003-07-25 SI SI200330881T patent/SI1526867T1/sl unknown
- 2003-07-25 EA EA200700196A patent/EA013966B1/ru not_active IP Right Cessation
- 2003-07-25 KR KR1020107011097A patent/KR20100077033A/ko not_active Application Discontinuation
- 2003-07-25 EA EA200500281A patent/EA009463B1/ru not_active IP Right Cessation
- 2003-07-25 ES ES03766302T patent/ES2285195T3/es not_active Expired - Lifetime
- 2003-07-25 WO PCT/EP2003/008229 patent/WO2004012759A2/de active Application Filing
- 2003-07-25 MX MXPA05001120A patent/MXPA05001120A/es active IP Right Grant
- 2003-07-25 CN CN200710127913XA patent/CN101099731B/zh not_active Expired - Fee Related
- 2003-07-25 PT PT03766302T patent/PT1526867E/pt unknown
- 2003-07-25 SG SG2007003890A patent/SG177004A1/en unknown
- 2003-07-25 EA EA200801236A patent/EA200801236A1/ru unknown
- 2003-07-25 US US10/522,426 patent/US7745387B2/en not_active Expired - Fee Related
- 2003-07-25 JP JP2004525322A patent/JP4727988B2/ja not_active Expired - Fee Related
- 2003-07-25 CN CNA038221160A patent/CN1681526A/zh active Pending
- 2003-07-25 BR BR0312981-0A patent/BR0312981A/pt not_active IP Right Cessation
- 2003-07-25 DE DE50307140T patent/DE50307140D1/de not_active Expired - Lifetime
- 2003-07-25 PL PL395151A patent/PL395151A1/pl unknown
- 2003-07-25 CA CA002493598A patent/CA2493598A1/en not_active Abandoned
- 2003-07-25 EP EP10000381A patent/EP2191838A1/de not_active Withdrawn
- 2003-07-25 AT AT07001689T patent/ATE468132T1/de not_active IP Right Cessation
- 2003-07-25 DK DK03766302T patent/DK1526867T3/da active
- 2003-07-25 CN CN2007101279144A patent/CN101099860B/zh not_active Expired - Fee Related
- 2003-07-25 KR KR1020057001341A patent/KR20050026513A/ko active Search and Examination
- 2003-07-25 PT PT07001689T patent/PT1779862E/pt unknown
-
2005
- 2005-01-06 IS IS7633A patent/IS2671B/is unknown
- 2005-01-20 IL IL16640105A patent/IL166401A0/xx not_active IP Right Cessation
- 2005-01-21 HR HR20050065A patent/HRP20050065A2/hr not_active Application Discontinuation
- 2005-01-25 ZA ZA200500726A patent/ZA200500726B/xx unknown
- 2005-02-24 NO NO20051002A patent/NO20051002L/no not_active Application Discontinuation
- 2005-11-04 HK HK05109837A patent/HK1081841A1/xx not_active IP Right Cessation
-
2007
- 2007-05-04 HR HR20070189A patent/HRP20070189A2/xx not_active Application Discontinuation
- 2007-07-02 CY CY20071100871T patent/CY1108052T1/el unknown
- 2007-10-31 HK HK07111782.2A patent/HK1108625A1/xx unknown
-
2009
- 2009-02-25 AU AU2009200748A patent/AU2009200748A1/en not_active Abandoned
- 2009-05-06 IS IS8817A patent/IS8817A/is unknown
-
2010
- 2010-03-18 IL IL204577A patent/IL204577A/en not_active IP Right Cessation
- 2010-04-01 HR HR20100187A patent/HRP20100187A2/xx not_active Application Discontinuation
- 2010-04-13 US US12/759,299 patent/US20100247451A1/en not_active Abandoned
- 2010-04-13 US US12/759,321 patent/US20100247452A1/en not_active Abandoned
- 2010-04-13 US US12/759,275 patent/US20100247450A1/en not_active Abandoned
- 2010-07-02 IS IS8909A patent/IS8909A/is unknown
- 2010-07-09 JP JP2010157094A patent/JP2010280672A/ja not_active Withdrawn
- 2010-07-09 JP JP2010157092A patent/JP2010280670A/ja not_active Withdrawn
- 2010-07-09 JP JP2010157093A patent/JP2010280671A/ja not_active Withdrawn
- 2010-07-29 CY CY20101100712T patent/CY1110713T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1526867T3 (da) | Erythropoietin i subpolycytæmiske doser | |
Yu et al. | Effects of photostimulation on wound healing in diabetic mice | |
Mirhoseini et al. | Myocardial revascularization by laser: a clinical report | |
DE3880318D1 (de) | Polypeptide mit kollagen typ iv aktivitaet. | |
BR9907273A (pt) | Prótese, artigo, válvura cardìaca protética, e, processos para produzir uma prótese para um paciente humano, para modificar um substrato, para associar células endoteliais com um substrato, para distribuir um artigos médico para uso por profissionais de cuidados com a saúde, e para produzir um material biocompatìvel | |
ATE469654T1 (de) | Verwendung des erythropoietins zur regeneration von lebergewebe | |
ES2162331T3 (es) | Utilizacion del factor de crecimiento del tejido nervioso para conservacion, cultivo o tratamiento de la cornea. | |
AU754874B2 (en) | A method for inducing production of growth factors | |
NO20021410L (no) | Forebygging og behandling av blodkoagulasjons-relaterte sykdommer | |
Becker | Effects of electrically generated silver ions on human cells and wound healing | |
Yamaguchi et al. | Skin grafting: surgical techniques | |
Bocchi et al. | Pathological scar formation in burns: new biochemical and molecular factors in the healing process | |
Senges et al. | Effect of brief periods of paced ventricular tachycardia on coronary blood flow in dogs before and after graded coronary stenosis | |
JPS6442441A (en) | Macrophage activator | |
RU93037867A (ru) | Способ лечения длительно незаживающих ран и трофических язв кожных покровов |